PLP 139-151 is a peptide fragment derived from proteolipid protein (PLP), which is primarily studied in the context of immunology and neuroscience. It is widely used in research to investigate autoimmune diseases, particularly multiple sclerosis (MS). This peptide is employed to induce experimental autoimmune encephalomyelitis (EAE) in animal models, a condition that mimics MS in humans. By studying the immune response triggered by PLP 139-151, researchers aim to better understand the mechanisms of autoimmune attacks on the central nervous system. Additionally, it serves as a tool for testing potential therapeutic interventions, such as immunomodulatory drugs or vaccines, to prevent or treat autoimmune disorders. Its application is crucial for advancing knowledge in neuroimmunology and developing targeted therapies for MS and related conditions.